The sulfonamide derivatives differ from compound to compound not only in scope and effectiveness of chemotherapeutic action4 but also in their pharmacological properties."8 It becomes important, therefore, with each new compound introduced, after preliminary studies in animals, to determine the facts concerning these properties in man. In this paper are recorded observations in man on the absorption, excretion, diffusion into body fluids, and acetylation of sulfathiazole,t recently introduced by Fosbinder and Walter8 and Lott and Bergeim,17 and already shown1 2'6' 14, 21 to be chemotherapeutically active in a variety of experimental infections in mice as well as bacteriostatic in vitro.11' 13 14 The studies were made in part on individuals not receiving chemotherapeutic treatment, in part on patients with acute infections, mostly pneumococcal pneumonia, undergoing therapy with sulfathiazole.
absorbed from the gastro-intestinal tract, commonly attaining its peak of concentration in the blood less than 4 hours after a single oral dose. Recovery of the ingested sulfathiazole in the urine varied from about 60 per cent to 93 per cent in 24 hours and was practically quantitative following intravenous administration of the sodium salt. The proportion of the drug conjugated was low in most instances.
Materials and methods
Observations on the rate of absorption of sulfathiazole from the gastrointestinal tract, as measured by frequent determinations of blood concentration following a single dose of 0.06 gm./K per os, were made in one normal adult male and compared with the data obtained following similar single oral and intravenous doses, respectively, of sodium sulfathiazole in another individual. In addition, in order to establish the range of individual variation, the blood concentration attained 4 hours after a single initial oral dose of 4.0 gm. of sulfathiazole was determined in 32 patients.
Ten studies on the excretion of sulfathiazole in the urine, either following a single dose of 0.06 gm./K or an initial dose of 4.0 gm. per os followed by 1.0 gm. every 4 hours, were conducted in 9 individuals over varying periods of time.
The rate and degree of diffusion of sulfathiazole into body-fluids, as compared with simultaneously determined blood concentrations, were studied in 14 instances, either after a single dose of 4.0 gm. of sulfathiazole given orally or an initial dose of 4.0 gm. followed by 1.0 gm. every 4 hours. Four of these observations were on pleural effusions, 4 were on ascitic fluids from cases of hepatic cirrhosis, and 6 were on non-inflammatory spinal fluids from patients receiving diagnostic lumbar puncture. A few similar studies with sulfamethylthiazole are included.
In order to determine the range of variation in blood concentration that may occur in patients under continued treatment with sulfathiazole, daily blood determinations were made just prior to the 8:00 A. M. dose in a series of patients most of whom had pneumococcal pneumonia. The results in 82 courses of therapy in 79 cases, in whom the treatment consisted of an initial dose per os of 4.0 gm. followed by 1.0 gm. q. 4 h. for 5 to 8 days, are presented.
In all the foregoing observations the concentration of both free and total sulfathiazole was determined, thus providing a mass of material on the degree of acetylation of sulfathiazole which occurs in man.
The Fig. 1 . It will be noted that the highly soluble sodium salt was absorbed very rapidly from the gastro-intestinal tract, the curve being almost the same as that obtained following intravenous injection. In the first 6-hour period approximately 40 per cent and 36 per cent, respectively, of the administered drug were recovered in the urine.
Judging from previous experience with sulfapyridine,5 absorption of sulfathiazole from the gastro-intestinal tract may be expected to vary considerably from individual to individual, particularly in the presence of disease. The results of observations on blood concentration 4 hours after a single initial dose of 4.0 gm. of sulfathiazole in 32 cases, of whom 17 had pneumococcal pneumonia, 4 had other infections, and 11 had miscellaneous conditions not under treatment, are shown in Table 1 . The concentrations found ranged from 1.4 to 8.1 mgm. per cent, the majority falling between 3.0 and 5.9 mgm. per cent. These figures obviously indicate a consider- In order to obtain information concerning variations in the amount of sulfathiazole excreted in the urine in cases under con-tinued treatment, similar observations were made in 7 patients over periods of time ranging from 2 to 9 days. The summarized data are shown in Table 3 , from which it will be seen that the amount of administered drug recovered in the urine varied considerably from patient to patient. While differences in renal function might obviously be a factor influencing the output of sulfathiazole in the urine, it would seem more probable in this group of cases, at least, that variations in the amount of drug absorbed were of more significance, inasmuch as the maxitium concentration attained in the blood was in no case higher than usual with the dosage employed.
Diffusion into body fluids
Data concerning the rate and degree of diffusion of sulfathiazole into pleural and ascitic fluids are shown in Table 4 . In seven observations 4 hours after an oral dose of 4.0 gm. of sulfathiazole the The failure of sulfathiazole to diffuse readily into the spinal fluid is in marked contrast with the diffusibility of sulfanilamide and sulfapyridine. A comparison of sulfathiazole and sulfapyridine is shown in Fig. 2 . Whether sulfathiazole will enter the spinal fluid heart failure were excluded and are commented on separately below. The 4-hour blood concentration determinations were made on samples of blood collected four hours after the initial dose of 4.0 gm. and just prior to the first 1.0 gm. dose of the maintenance treatment. All other determinations, except those recorded in solid dots, were made on samples of blood collected at approximately 8:00 A. M., four hours after the regular 4:00 A. M. dose of 1.0 gm. and just before the 8:00 A. M. dose. The solid dots on the 6th, 7th, and 8th days record blood levels in a few patients made on the day following discontinuance of therapy. The day on which therapy was begun was considered the first day of treatment, irrespective of the time when sulfathiazole was started, the second day of treatment was considered as beginning at 7:00 A. M. on the following day, and so on.
The data recorded in. Fig. 3 show a wide variation in blood levels during the early hours of treatment. While there is still considerable variation by the third day and later, a much greater tendency of the values to group about the median is apparent. The slight trend toward a lower median as time progresses is, perhaps, related to increased renal excretion with clinical improvement and the establishment of convalescence. The range of blood concentrations with sulfathiazole therapy appears to be quite similar to that with sulfapyridine, the median to be somewhat lower than that for total sulfapyridine.
Acetylation of sulfathiazole
: One of the major problems associated with the use of sulfapyridine as a chemotherapeutic agent is the highly variable and unpredictable degree of conjugation to the acetyl derivative over a wide range from 15 to 75 per cent or more which commonly occurs in patients under treatment with this drug.3 ', 25 This difficulty, on the other hand, is not encountered to more than a minor extent with sulfanilamide.19 24 The degree of acetylation of sulfathiazole has been studied from day to day in a large series of patients. As representative of the group the data on the same patients included in Fig. 3 are shown in Fig. 4 , which records the daily per cent of total sulfathiazole in the blood that was acetylated. It will be seen that the degree of acetylation, with few exceptions, falls within the relatively narrow range between 0 and 30 per cent, the median being approximately 12 per cent. The conjugation of sulfathiazole in man, therefore, is apparently comparable in degree to that of sulfanilamide and is not excessive, as it frequently is with sulfapyridine.
Reference to Tables 2 and 3 will show that the percentage of acetylated sulfathiazole found in the urine is also relatively low, rarely exceeding 25 per cent and that only after 18 hours or more following the last dose of sulfathiazole administered. Acetyl sulfathiazole, however, is highly insoluble'0 and examination of urinary sediments has shown that it may be present in crystalline form in the urine (Figs. 5 and 6 ). While we have not as yet encountered anuria due to obstruction of urinary flow by sulfathiazole concretions, Gross, and Horack22 have reported a case in which concretions obstructing the renal tubules and in the renal pelves and in the bladder were discovered at autopsy. Table 4 indicates. that acetylated sulfathiazole does not diffuse so rapidly into pleural and ascitic fluids as does free sulfathiazole, only free drug being present in the 4-hour specimens even when the acetyl compound was present in the blood. It has already been pointed out that little or no acetylated sulfathia-zole was found in spinal fluids even as long as 24 to 43 hours after the initial dose of the drug was administered.
Analysis of the data in
The effect of heart failure and impaired renal function on the con, centration of free and acetylated sulfathiazole in the blood In the series of patients which we have treated with sulfathiazole up to the present time, there have been two with congestive heart failure, two with seriously impaired renal function. All were started on an initial dose of 4.0 gm. followed by 1.0 gm. q. 4 h. Observations on these cases are presented in Table 6 . In Case C.B., with fairly severe congestive failure and diminished output of urine, the blood level of total sulfathiazole rose progressively to 15.9 mgm. per cent on the fourth day and the degree of acetylation was excessively high, possibly due to continued recirculation of the drug through the liver; in Case J. L. with less severe failure the concentration of sulfathiazole in the blood increased rapidly but was quickly controlled by promptly cutting the dosage in half. In both cases with impaired renal function and azotemia the blood levels rose rapidly to excessively high levels and diminished quite slowly when treatment was discontinued. In Case F. M. acetylation also was excessively high. These cases serve to illustrate the caution required in the treatment of patients who have cardiac or renal failure. Discussion These observations on the pharmacological properties of sulfathiazole indicate that absorption and excretion of the drug are sufficiently rapid to require spacing of doses at four-hour intervals in order to maintain adequate and relatively constant blood concentrations throughout the period of therapy. They also show that an initial dose of 4.0 gm. followed by 1.0 gm. every four hours serves to establish promptly and to maintain an appropriate blood level in the great majority of patients. Under special circumstances, however, particularly in patients with congestive heart failure or with significantly impaired renal function, these doses may be excessive and may quickly result in undesirably high concentrations of sulfathiazole in the blood. The dosage in all such patients should be regulated by careful attention to blood levels.
The ready diffusion of sulfathiazole into pleural fluid suggests that this compound should often be chemotherapeutically effective in the early stages of infected pleural effusions associated with the coccal pneumonias, at least before they have developed into frankly purulent empyemas. On the other hand, the relatively poor diffusion of sulfathiazole into spinal fluid suggests the possibility that it may not be a satisfactory agent for the treatment of meningitis. As already pointed out, however, observations on non-inflammatory spinal fluids may not be applicable and the question needs further study in actual cases of acute meningitis.
In harmony with the observations of others, it has been found that sulfathiazole is not acetylated to an excessive degree except in very rare instances. In this respect sulfathiazole possesses a con-siderable advantage over sulfapyridine, not only because the amount of inactive acetyl derivative in patients under treatment will be relatively small but also because the necessity for determining both the total and free concentrations of sulfathiazole in the blood is eliminated, the latter being adequate for routine purposes. While the low degree of acetylation of sulfathiazole is comparable to that of sulfanilamide, it must be borne in mind, however, that acetylsulfathiazole, unlike acetylsulfanilamide, is highly insoluble and consequently may readily precipitate out in crystalline form in the urine with resultant interference with urinary flow. As stated above, this has been shown to occur in experimental animals, though less frequently than in the case with sulfapyridine.' For this reason patients under treatment with sulfathiazole should have fluids forced sufliciently to prevent the urine from becoming concentrated. Particular caution should be observed in patients who are dehydrated or who have congestive heart failure or renal disease.
Sumnmary
Observations on the absorption, excretion, diffusion, and acetylation of sulfathiazole in man have been presented. They show (1) that sulfathiazole is readily absorbed and excreted; (2) that there is considerable individual variation in capacity to absorb the drug, though not enough to interfere with the use of a standard dosage in the great majority of patients; (3) that sulfathiazole readily diffuses into pleural and ascitic fluids but very poorly into non-inflammatory spinal fluids; and (4) that acetylation of sulfathiazole is not excessive, only rarely exceeding 30 per cent in the blood and urine, but because of its high insolubility precipitation of crystals of acetyl sulfathiazole may, nevertheless, occur in the urine. Finally, some of the clinical implications of these observations on the pharmacological properties of sulfathiazole have been briefly discussed. . with temporary oliguria and albuminuria. Analysis of the dried crystalline sediment showed that 86 per cent of the total sulfathiazole was acetylated.
